Clover Biopharmaceuticals Ltd. stock analysis
Want to see HK:2197 full AI Analyst Report?
Clover operates across the full vaccine and biologics value chain, from research through commercialization. This integrated focus can support continuity between scientific development, regulatory execution, manufacturing readiness, and eventual product sales as the company builds its longer-term pipeline.
Protein engineering and adjuvant technologies provide a defined scientific foundation for developing immunology-focused products beyond a single commercial program. These capabilities may support differentiated vaccine candidates and create a platform for future development if translated into approved products.
Participation in public-sector procurement and international distribution gives Clover potential access to institutional buyers and multiple geographic markets. That commercial reach can broaden demand opportunities and provide channels for monetizing approved vaccines and other biologic products over time.
A roughly 93% revenue decline indicates that the company’s current commercial base is highly unstable and vulnerable to changes in vaccine demand, tenders, or public-health policy. Such contraction reduces operating leverage and makes funding future research and commercialization more difficult.
Persistent negative shareholder equity reflects accumulated losses and materially limits financial flexibility. It also makes conventional leverage measures less informative, heightens sensitivity to refinancing or going-concern pressures, and can constrain Clover’s ability to invest in its pipeline without further external support.
Multi-year negative operating and free cash flow shows that the business has not yet generated sustainable internal funding. Continued cash burn increases reliance on external financing or asset reductions, potentially limiting research, manufacturing, and commercialization investment over the next several quarters.
Clover Biopharmaceuticals Ltd. ( ($HK:2197) ) just unveiled an announcement. Clover Biopharmaceuticals reported positive preliminary Phase 2 data from an Australian trial of its combination respiratory vaccines SCB-1022 and SCB-1033
Clover Biopharmaceuticals Ltd. ( ($HK:2197) ) has shared an announcement. Clover Biopharmaceuticals has issued a supplemental announcement clarifying enhanced measures to ensure its grantors comply with Hong Kong’s Model Code
The latest update is out from Clover Biopharmaceuticals Ltd. ( ($HK:2197) ). Clover Biopharmaceuticals has called its annual general meeting for June 18, 2026, in Chengdu, where shareholders will vote
Clover Biopharmaceuticals Ltd. ( ($HK:2197) ) has shared an update. Clover Biopharmaceuticals has provided additional details on its settlement agreement with Gavi, the Vaccine Alliance, outlining a capped and structured
Clover Biopharmaceuticals Ltd. ( ($HK:2197) ) just unveiled an announcement. Clover Biopharmaceuticals has completed enrollment in an Australian Phase 2 clinical trial evaluating two respiratory combination vaccine candidates, SCB-1022 and
The latest update is out from Clover Biopharmaceuticals Ltd. ( ($HK:2197) ). Clover Biopharmaceuticals has granted 10,195,500 share options and 8,965,000 restricted share units to 43 eligible participants under its
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |
